ROSSARI BIOTECH LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 699.2 INR | -0.30% |
|
-2.07% | -12.51% |
| May. 01 | Rossari Biotech's Consolidated Profit Climbs in FIscal Q4 | MT |
| Apr. 30 | Transcript : Rossari Biotech Limited, Q4 2024 Earnings Call, Apr 30, 2024 |
Valuation
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 53,775 | 50,189 | 32,878 | 38,629 | - | - |
| Enterprise Value (EV) 1 | 52,876 | 50,189 | 32,878 | 37,399 | 38,629 | 38,629 |
| P/E ratio | 66.9 x | 51.5 x | 30.8 x | 28.7 x | 23.5 x | 19.1 x |
| Yield | 0.05% | 0.05% | 0.08% | 0.44% | 0.37% | 0.72% |
| Capitalization / Revenue | 7.58 x | 3.38 x | 1.99 x | 2.04 x | 1.85 x | 1.58 x |
| EV / Revenue | 7.58 x | 3.38 x | 1.99 x | 2.04 x | 1.85 x | 1.58 x |
| EV / EBITDA | 43.5 x | 27.4 x | 14.7 x | 15 x | 13.1 x | 11 x |
| EV / FCF | -521 x | -566 x | 27.5 x | -310 x | 105 x | 28.2 x |
| FCF Yield | -0.19% | -0.18% | 3.64% | -0.32% | 0.95% | 3.55% |
| Price to Book | 13.2 x | 6.23 x | 3.59 x | 3.74 x | 3.24 x | 2.84 x |
| Nbr of stocks (in thousands) | 51,929 | 55,056 | 55,155 | 55,247 | - | - |
| Reference price 2 | 1,036 | 911.6 | 596.1 | 699.2 | 699.2 | 699.2 |
| Announcement Date | 5/14/21 | 5/20/22 | 4/29/23 | 4/29/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 6,001 | 7,093 | 14,830 | 16,559 | 18,306 | 20,907 | 24,432 |
| EBITDA 1 | - | 1,236 | 1,834 | 2,230 | 2,499 | 2,949 | 3,500 |
| EBIT 1 | - | 1,008 | 1,354 | 1,601 | 1,895 | 2,214 | 2,698 |
| Operating Margin | - | 14.21% | 9.13% | 9.67% | 10.35% | 10.59% | 11.04% |
| Earnings before Tax (EBT) 1 | - | 1,068 | 1,363 | 1,442 | 1,776 | 2,173 | 2,676 |
| Net income 1 | - | 802.2 | 976.7 | 1,073 | 1,307 | 1,645 | 2,016 |
| Net margin | - | 11.31% | 6.59% | 6.48% | 7.14% | 7.87% | 8.25% |
| EPS 2 | - | 15.47 | 17.70 | 19.38 | 23.62 | 29.80 | 36.53 |
| Free Cash Flow 1 | - | -103.2 | -88.67 | 1,195 | -124.5 | 366.5 | 1,371 |
| FCF margin | - | -1.45% | -0.6% | 7.22% | -0.67% | 1.75% | 5.61% |
| FCF Conversion (EBITDA) | - | - | - | 53.59% | - | 12.43% | 39.18% |
| FCF Conversion (Net income) | - | - | - | 111.43% | - | 22.28% | 68.01% |
| Dividend per Share 2 | - | 0.5000 | 0.5000 | 0.5000 | 3.050 | 2.600 | 5.000 |
| Announcement Date | 10/1/20 | 5/14/21 | 5/20/22 | 4/29/23 | 4/29/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,182 | 2,311 | 3,845 | 4,284 | 4,389 | 4,347 | 4,254 | 3,893 | 4,065 | 4,106 | 4,392 | 4,718 | 4,843 |
| EBITDA 1 | 352.1 | 371.2 | 439.7 | 469 | 523.1 | 577.3 | 565.4 | 541.6 | 545.8 | 577.5 | 623.5 | 629.5 | 654 |
| EBIT 1 | - | - | - | - | 357.7 | 424.1 | 409.1 | 382.1 | - | 436 | 454 | 467 | 494 |
| Operating Margin | - | - | - | - | 8.15% | 9.76% | 9.62% | 9.81% | - | 10.62% | 10.34% | 9.9% | 10.2% |
| Earnings before Tax (EBT) 1 | - | - | - | - | 342.7 | 387 | 336.2 | 346.5 | - | 394.6 | 413 | 430 | 486 |
| Net income 1 | - | 245.2 | 262.3 | 225.4 | 240.8 | 286.8 | 239.2 | 256.8 | 289.8 | 292.2 | 308 | 322 | 356 |
| Net margin | - | 10.61% | 6.82% | 5.26% | 5.49% | 6.6% | 5.62% | 6.6% | 7.13% | 7.12% | 7.01% | 6.82% | 7.35% |
| EPS 2 | - | - | - | - | - | - | 4.320 | 4.630 | - | 5.280 | 5.600 | 5.800 | 6.600 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 5/14/21 | 7/30/21 | 10/30/21 | 2/14/22 | 5/20/22 | 8/6/22 | 11/5/22 | 2/4/23 | 4/29/23 | 7/29/23 | - | - | - |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | 900 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -103 | -88.7 | 1,195 | -125 | 367 | 1,371 |
| ROE (net income / shareholders' equity) | - | 23.1% | 16.1% | 12.5% | 13.5% | 14.7% | 15.6% |
| ROA (Net income/ Total Assets) | - | - | 10.7% | 8.17% | 9% | 10.4% | 11.4% |
| Assets 1 | - | - | 9,090 | 13,121 | 14,696 | 15,814 | 17,684 |
| Book Value Per Share 2 | - | 78.70 | 146.0 | 166.0 | 187.0 | 216.0 | 247.0 |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | - | 581 | 382 | 329 | 967 | 1,762 | 635 |
| Capex / Sales | - | 8.19% | 2.58% | 1.99% | 5.24% | 8.43% | 2.6% |
| Announcement Date | 10/1/20 | 5/14/21 | 5/20/22 | 4/29/23 | 4/29/24 | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
699.2
INR
Average target price
862.3
INR
Spread / Average Target
+23.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.51% | 464M | |
| +17.80% | 66.43B | |
| +2.92% | 49.89B | |
| +19.98% | 41.88B | |
| +20.88% | 26.48B | |
| +12.04% | 19.68B | |
| +1.27% | 17B | |
| -22.98% | 16.12B | |
| +2.77% | 15.28B | |
| -9.25% | 15.18B |
- Stock Market
- Equities
- ROSSARI Stock
- Financials Rossari Biotech Limited
